Management Team
Sam Chu, Ph.D.
President, CEO & CSO
Dr. Chu has over 25 years research and management experience in Pharmaceutical Industry. Before founding JiaRay in 2013, Dr. Chu worked as Senior Scientist at Agouron/Pfizer; Director of Chemistry at Quorex Pharmaceuticals; Research Fellow at Takeda Pharmaceuticals and Research Fellow at CrownBioscience.
Yuqiang Wu
Vice President, COO
Mr. Wu has over 15 years operation experience in Construction Industry. Before joining JiaRay in 2016, Mr. Wu managed many multi million dollar projects and oversaw all project operations
Bo Zhang, CPA
Financial Controller
Mr. Zhang has over 25 years experience in Accounting, Auditing and Taxation.
Research Team
Sam Chu, Ph.D.
(Medicinal Chemistry)
Structure based drug design, computational modeling, organic synthesis, parallel synthesis and peptide chemistry;
Over 25 years pharmaceutical industry experience
Ron Christopher, Ph.D., D.A.B.T., FCP
( DMPK, Toxicology & Clinical Pharmacology)
Clinical pharmacology, toxicology, and DMPK in drug development to support the safe and effective use of pharmaceutical products as specified by IND, BLA, and NDA requirements;
Directing and managing nonclinical/early clinical development activities supporting development of small molecules, protein conjugates, monoclonal antibodies, cellular therapies, infectious disease and gene therapies in the pharmaceutical industry;
Over 30 years’ experience in the pharmaceutical and biotech industries with extensive experience in pharmaceutical (small molecule and biotherapeutics) research and development.
Ron de Jong, Ph.D.
(Biology & Pharmacology)
Cell-based assays for drug screening, target validation, ex vivo pharmacodynamic assays and in vivo efficacy and pharmacodynamic studies;
20 years of industry experience in cellular pharmacology, drug discovery and preclinical drug development of small molecule drug candidates against various target classes and in multiple therapeutic areas.
Gaylen Zentner, Ph.D.
(Analytical Chemistry, Pharmaceutical Chemistry)
All technical, manufacturing, and documentation aspects of Chemistry, Manufacturing & Control (CMC) sections of regulatory submissions; drug substance and drug product; sophisticated drug delivery systems, controlled release, solubilization, and bioavailability enhancement;
33 years experience.
Kraig Yager, Ph.D.
(Medicinal Chemistry, Process Chemistry)
API process development and manufacturing, CMC drug substance sections of regulatory submissions, solubilization technologies;
20 years experience.
Mark Williams
(Pharmaceutical Chemistry)
Technical and manufacturing aspects of Chemistry, Manufacturing & Control (CMC) sections of regulatory submissions; drug product manufacturing and characterization for clinical and commercial applications; oral solids (including controlled release) and sterile injectables;
36 years experience.
Taiping Chen, DVM, Ph.D.
(Cell Biology, Translational Oncology)
In vivo animal tumor model, including CDX, PDX (solid and leukemia) pharmacology, genomic and biomarker profiling platforms;
25 years experience